Open Access203Pb-VMT-α-NET Scintigraphy of a Patient With Neuroendocrine Tumor
Author(s) -
Dirk Müller,
Hendrik Herrmann,
Michael Schultz,
Christoph Solbach,
Thomas Jens Ettrich,
Vikas Prasad
Publication year - 2022
Publication title -
clinical nuclear medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.637
H-Index - 57
eISSN - 1536-0229
pISSN - 0363-9762
DOI - 10.1097/rlu.0000000000004464
Subject(s) - medicine , neuroendocrine tumors , nuclear medicine , scintigraphy , radiology
In an end-stage midgut neuroendocrine tumor patient with carcinoid heart disease, right ventricular dysfunction, mildly reduced renal function, and refractory to 6 cycles of 177 Lu-HA-DOTATATE therapy, planar, and 22 hours SPECT/CT images were acquired after injection of 224 MBq of 203 Pb-VMT-α-NET to assess the feasibility of performing 212 Pb-VMT-α-NET therapy. A comparison of the 1.5 and 22 hours SPECT/CT images with 68 Ga-HA-DOTATATE PET/CT showed high uptake of 203 Pb-VMT-α-NET in liver metastases matching with the results of the PET/CT investigation.